Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Fang Chen, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Abstract
= 0.179). Obviously, EGFR-TKIs for EGFR mutate NSCLC patients when concurrent PIK3CA mutations have a worse prognosis and shorter survival time.
Topics & Concepts
MedicineEpidermal growth factor receptorLung cancerTyrosine kinaseMutationCancer researchMutantInternal medicineOncologyKinaseCancerBiologyReceptorGeneGeneticsLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies